HIV Treatment Information for Children
Get Drug Information for Pediatric Patients
*Please refer to the most current drug label for pediatric patients with renal impairment.
For body weight- and BSA-based dosing in pediatric patients, do not exceed the recommended adult daily dose.
General Considerations:
Before prescribing tablets/capsules, pediatric patients should be assessed for the ability to swallow.
Filter by
| Brand | Generic | Drug Class | Dosage Form | Weight | Age | Pediatric Dosing | Visit Drugs@FDA to view |
|---|---|---|---|---|---|---|---|
| Atripla* | efavirenz 600 mg emtricitabine 200 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | ≥40 kg | One tablet once daily on an empty stomach, preferably at bedtime | Atripla Label | |
| Biktarvy* | bictegravir 50 mg emtricitabine 200 mg tenofovir alafenamide 25 mg |
Combination Products | Oral Tablet | ≥ 25 kg | One tablet once daily with or without food | Biktarvy Label | |
| Cimduo* | lamivudine 300 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | ≥ 35 kg | One tablet once daily with or without food | Cimduo Label | |
| Combivir* | zidovudine 300 mg lamivudine 150 mg |
Combination Products | Oral Tablet | ≥ 30 kg | One tablet twice daily | Combivir Label | |
| Complera* | emtricitabine 200 mg rilpivirine 25 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | ≥ 35 kg | One tablet once daily with food | Complera Label | |
| Delstrigo | doravirine 100 mg lamivudine 300 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | None available | Delstrigo Label | ||
| Descovy* | emtricitabine 200 mg tenofovir alafenamide 25 mg |
Combination Products | Oral Tablet | Dosing for ≥ 25 kg No dosing available for < 35 kg when coadministered with an HIV-1 protease inhibitor with ritonavir or cobicistat |
One tablet once daily with or without food | Descovy Label | |
| Dovato | dolutegravir 50 mg lamivudine 300 mg |
Combination Products | Oral Tablet | None available | Dovato Label | ||
| Epzicom* | abacavir 600 mg lamivudine 300 mg |
Combination Products | Oral Tablet | ≥ 25 kg | One tablet once daily with or without food | Epzicom Label | |
| Evotaz | atazanavir 300 mg cobicistat 150 mg |
Combination Products | Oral Tablet | ≥ 35 kg | For treatment-naive and -experienced patients weighing ≥ 35 kg: One tablet once daily with food | Evotaz Label | |
| Genvoya* | elvitegravir 150 mg cobicistat 150 mg tenofovir alafenamide 10 mg emtricitabine 200 mg |
Combination Products | Oral Tablet | ≥ 25 kg | One tablet once daily with food | Genvoya Label | |
| Juluca | dolutegravir 50 mg rilpivirine 25 mg |
Combination Products | Oral Tablet | None available | Juluca Label | ||
| Kaletra | lopinavir 100 mg and ritonavir 25 mg lopinavir 200 mg and ritonavir 50 mg |
Combination Products | Oral Tablet | ≥ 14 days | Once daily dosing regimen not recommended. Twice daily dose is based on body weight or body surface area. Please see Full Prescribing Information for dosing regimen. | Kaletra Label | |
| Kaletra | lopinavir 80 mg/mL and ritonavir 20 mg/mL | Combination Products | Oral Solution | ≥ 14 days | Once daily dosing regimen not recommended. Twice daily dose is based on body weight or body surface area. Must be given with food. Please see Full Prescribing Information for dosing regimen. | Kaletra Label | |
| Odefsey* | emtricitabine 200 mg rilpivirine 25 mg tenofovir alafenamide 25 mg |
Combination Products | Oral Tablet | ≥ 35 kg | One tablet once daily with a meal | Odefsey Label | |
| Prezcobix | darunavir 800 mg cobicistat 150 mg |
Combination Products | Oral Tablet | ≥ 40 kg | For treatment-naïve and treatment-experienced patients weighing ≥ 40 kg with no darunavir resistance associated substitutions: one tablet once daily with food | Prezcobix Label | |
| Stribild* | elvitegravir 150 mg cobicistat 150 mg emtricitabine 200 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | ≥ 35 kg | ≥ 12 years | One tablet once daily with food | Stribild Label |
| Symfi* | efavirenz 600 mg lamivudine 300 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | ≥ 40 kg | One tablet once daily on an empty stomach, preferably at bedtime | Symfi Label | |
| Symfi Lo* | efavirenz 400 mg lamivudine 300 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | ≥ 35 kg | One tablet once daily on an empty stomach, preferably at bedtime | Symfi Lo Label | |
| Symtuza | darunavir 800 mg cobicistat 150 mg emtricitabine 200 mg tenofovir alafenamide 10 mg |
Combination Products | Oral Tablet | None available | Symtuza Label | ||
| Triumeq* | dolutegravir 50 mg abacavir 600 mg lamivudine 300 mg |
Combination Products | Oral Tablet | ≥ 40 kg | One tablet once daily with or without food | Triumeq Label | |
| Trizivir* | abacavir 300 mg lamivudine 150 mg zidovudine 300 mg |
Combination Products | Oral Tablet | ≥ 40 kg | One tablet twice daily with or without food | Trizivir Label | |
| Truvada | emtricitabine (FTC), tenofovir disoproxil fumarate (TDF): 100 mg FTC/150 mg TDF 133 mg FTC/200 mg TDF 167 mg FTC/250 mg TDF |
Combination Products | Oral Tablet | Between 17 kg and < 35 kg | One tablet daily based on body weight. Please see Full Prescribing Information for dosing | Truvada Label | |
| Truvada | emtricitabine (FTC), tenofovir disoproxil fumarate (TDF): 200 FTC/300 mg TDF |
Combination Products | Oral Tablet | ≥ 35 kg | One tablet once daily with or without food | Truvada Label | |
| Emtriva | emtricitabine 200 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Capsule | ≥ 33 kg who can swallow an intact capsule | 3 months through 17 years of age | One capsule once daily with or without food | Emtriva Label |
| Emtriva | emtricitabine 10 mg/mL | Nucleoside Reverse Transcriptase Inhibitors | Oral Solution | 0-3 months: 3 mg per kg given once daily 3 months through 17 years of age: 6 mg per kg up to a maximum of 240 mg (24 mL) once daily May be taken without with or without food |
Emtriva Label | ||
| Epivir* | lamivudine 150 mg, 300 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 14 kg | ≥ 3 months | Dosing based on body weight using a 150 mg scored tablet or alternatively a non-scored 300 mg tablet with or without food. Please see Full Prescribing Information for dosing regimen. | Epivir Label |
| Epivir* | lamivudine 10 mg/mL | Nucleoside Reverse Transcriptase Inhibitors | Oral Solution | ≥ 3 months | 5 mg per kg twice daily or 10 mg per kg once daily (up to a maximum of 300 mg daily) with or without food | Epivir Label | |
| Retrovir* | zidovudine 100 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Capsule | ≥ 4 kg | 4 weeks to less than 18 years | Dosage should be calculated based on body weight or BSA not to exceed adult dose. Please see Full Prescribing Information for dosing regimen. | Retrovir Label |
| Retrovir* | zidovudine 10 mg/mL | Nucleoside Reverse Transcriptase Inhibitors | Oral Syrup | ≥ 4 kg | 4 weeks to less than 18 years | Dosage should be calculated based on body weight or BSA not to exceed adult dose. Please see Full Prescribing Information for dosing regimen. | Retrovir Label |
| Retrovir* | zidovudine 20-ml single-use vial (10 mg/mL) | Nucleoside Reverse Transcriptase Inhibitors | Intravenous Injection | Neonates unable to receive oral dosing may be administered RETROVIR intravenously. Start neonatal dosing within 12 hours after birth and continue through 6 weeks of age. |
1.5mg/kg infused over 30 minutes every 6 hours. Total dose is 6mg/kg/day. Please see Full Prescribing Information for oral dosing. | Retrovir Label | |
| Temixys* | lamivudine 300 mg tenofovir disoproxil fumarate 300 mg |
Nucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 35 kg | One tablet once daily with or without food | Temixys Label | |
| Videx* | didanosine 2 g, 4 g | Nucleoside Reverse Transcriptase Inhibitors | Oral Powder for Solution | ≥ 2 weeks to 18 years old | Dosing is based on body weight and administered on an empty stomach at least 30 minutes before or 2 hours after eating. Please see Full Prescribing Information for details | Videx Label | |
| Videx EC* | didanosine delayed-release capsule 125 mg, 200 mg, 250 mg, 400 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Capsule | ≥ 20 kg | ≥ 6 years to 18 years | Dosing is based on body weight and administered on an empty stomach once daily. Please see Full Prescribing Information for dosing. | Videx EC Label |
| Viread* | tenofovir disoproxil fumarate 300 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 35 kg | ≥ 2 years | For patients weighing at least 35 kg, one tablet (300 mg) taken orally once daily without regard to food | Viread Label |
| Viread* | tenofovir disoproxil fumarate 150 mg, 200 mg, 250 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 17 kg - < 35 kg | ≥ 2 years | For patients weighing at least 17 kg who can swallow an intact tablet, one tablet (150 mg, 200 mg, 250 mg, or 300 mg based on body weight) once daily taken orally without regard to food. Please see Full Prescribing Information for details | Viread Label |
| Viread* | tenofovir disoproxil fumarate 40 mg per gram of powder | Nucleoside Reverse Transcriptase Inhibitors | Oral Powder | ≥ 10 kg | ≥ 2 years | For patients weighing at least 10 kg and unable to swallow a tablet, 8 mg per kg oral powder (up to a maximum of 300 mg) taken once daily with soft food. Please see Full Prescribing Information for details | Viread Label |
| Zerit | stavudine 15 mg, 20 mg, 30 mg, 40 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Capsule | Birth to 13 days old | 0.5 mg/kg given every 12 hours | Zerit Label | |
| Zerit | stavudine 15 mg, 20 mg, 30 mg, 40 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Solution | < 30 kg | ≥ 14 days | 1 mg/kg given every 12 hours | Zerit Label |
| Zerit | stavudine 15 mg, 20 mg, 30 mg, 40 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Capsule | ≥ 30 kg | Use the recommended adult dosage | Zerit Label | |
| Ziagen | abacavir 300 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 14 kg | ≥ 3 months | Dosing based on body weight given once or twice daily. Please see Full Prescribing Information for details | Ziagen Label |
| Ziagen | abacavir 20 mg/ mL | Nucleoside Reverse Transcriptase Inhibitors | Oral Solution | ≥ 3 months | 8 mg per kg orally twice daily or 16 mg per kg orally once-daily (up to a maximum of 600 mg daily) | Ziagen Label | |
| Edurant | rilpivirine 25 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 35 kg | ≥ 12 years | One tablet once daily with a meal | Edurant Label |
| Intelence | etravirine 25, 100, 200 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 10 kg | ≥ 2 years to less than 18 years | Dosing based on body weight not exceeding the recommended adult dosage and taken following a meal. Please see Full Prescribing Information for dosing. | Intelence Label |
| Pifeltro | doravirine 100 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | None available | Pifeltro Label | ||
| Rescriptor | delavirdine 200 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 16 years | None available for < 16 years. If ≥16 years, use adult dosing | Rescriptor Label | |
| Sustiva | efavirenz 600 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 3.5 kg | ≥ 3 months | Dosing based on body weight. Please see Full Prescribing Information for dosing. | Sustiva Label |
| Sustiva | efavirenz 50, 200 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Capsule | ≥ 3.5 kg | ≥ 3 months | Dosing based on body weight. Please see Full Prescribing Information for dosing. | Sustiva Label |
| Viramune* | nevirapine 200 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 15 days | Dosing based on BSA once daily for 14 days followed by twice daily thereafter. Total daily dose should not exceed 400 mg for any patient. Please see Full Prescribing Information for details. | Viramune Label | |
| Viramune* | nevirapine 50 mg/ 5mL | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Suspension | ≥ 15 days | Dosing based on BSA once daily for 14 days followed by twice daily thereafter. Total daily dose should not exceed 400 mg for any patient. Please see Full Prescribing Information for details. | Viramune Label | |
| Viramune XR* | nevirapine extended-release 400 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | ≥ 6 years to less than 18 years | Dosing based on BSA and must initiate therapy with immediate-release VIRAMUNE (tablets or oral suspension), at a dose not to exceed 200 mg per day, administered once daily for the first 14 days, followed by VIRAMUNE XR 400 mg once daily. Please see Full Prescribing Information for dosing details. | Viramune XR Label | |
| Aptivus | tipranavir 250 mg | Protease Inhibitors | Oral Capsule | ≥ 2 years to less than 18 years | Dosing based on body weight and BSA twice daily, and can be taken with or without meals. Not to exceed the recommended adult dose. Please see Full Prescribing Information for dosing details. | Aptivus Label | |
| Aptivus | tipranavir 100 mg/ mL | Protease Inhibitors | Oral Solution | ≥ 2 years to less than 18 years | Dosing based on body weight and BSA twice daily, and can be taken with or without meals. Not to exceed the recommended adult dose. Please see Full Prescribing Information for dosing details. | Aptivus Label | |
| Crixivan | indinavir 200 mg, 400 mg | Protease Inhibitors | Oral Capsule | None available | Crixivan Label | ||
| Invirase | saquinavir mesylate 500 mg | Protease Inhibitors | Oral Tablet | ≥ 16 years of age | See adult dosing recommendations. Please see Full Prescribing Information for dosing details. | Invirase Label | |
| Lexiva | fosamprenavir 700 mg | Protease Inhibitors | Oral Tablet | ≥ 4 weeks to less than 18 years | Dosing based on body weight and should not exceed the recommended adult dose. Take tablets with or without food. Please see Full Prescribing Information for dosing details. | Lexiva Label | |
| Lexiva | fosamprenavir 50 mg/ml | Protease Inhibitors | Oral Suspension | ≥ 4 weeks to less than 18 years | Dosing based on body weight and should not exceed the recommended adult dose. Take oral suspension with food. Please see Full Prescribing Information for dosing details. | Lexiva Label | |
| Norvir | ritonavir 100 mg | Protease Inhibitors | Oral Tablet | ≥ 1 month | The recommended twice daily dose with meals for children greater than one month of age is based on BSA and should not exceed 600 mg twice daily with meals. Please see Full Prescribing Information for details regarding dosing | Norvir Label | |
| Norvir | ritonavir 100 mg/packet | Protease Inhibitors | Oral Powder | ≥ 1 month | The recommended dosing is increments of 100 mg. NORVIR powder should not be used for doses less than 100 mg or for incremental doses between 100 mg intervals. Please see Full Prescribing Information for details regarding dosing for oral solution and oral powder | Norvir Label | |
| Norvir | ritonavir 80 mg/mL | Protease Inhibitors | Oral Solution | ≥ 1 month | NORVIR oral solution should not be administered to neonates before a postmenstrual age (first day of the mother’s last menstrual period to birth plus the time elapsed after birth) of 44 weeks has been attained. The recommended dose is based on BSA . Please see Full Prescribing Information for details regarding dosing for oral solution and oral powder | Norvir Label | |
| Prezista | darunavir 75 mg, 150 mg, 600 mg, 800 mg | Protease Inhibitors | Oral Tablet | ≥ 10 kg | ≥ 3 years to less than 18 years | Dosing based on body weight and should not exceed the adult dose and should be taken with ritonavir and with food. Please see Full Prescribing Information for details regarding dosing in oral tablet. | Prezista Label |
| Prezista | darunavir 100 mg/mL | Protease Inhibitors | Oral Suspension | ≥ 10 kg | ≥ 3 years to less than 18 years | Dosing based on body weight and should not exceed the adult dose and should be taken with ritonavir and with food. Please see Full Prescribing Information for details regarding dosing in oral suspension. | Prezista Label |
| Reyataz* | atazanavir sulfate 150 mg, 200 mg, 300 mg | Protease Inhibitors | Oral Capsule | ≥ 15 kg | ≥ 6 years to less than 18 years | Capsule dosage is based on body weight not to exceed the adult dose and must be taken with food. Please see Full Prescribing Information. | Reyataz Label |
| Reyataz* | atazanavir sulfate 50 mg/packet | Protease Inhibitors | Oral Powder | ≥ 5 kg | ≥ 3 months | Oral powder dosage must be taken with ritonavir and food and should not be used in pediatric patients who weigh less than 5 kg. Dosage is based on body weight, please see Full Prescribing Information. | Reyataz Label |
| Viracept | nelfinavir mesylate 250 mg, 625 mg | Protease Inhibitors | Oral Tablet | ≥ 10 kg | 2 to less than 13 years | • Recommended dosing based on body weight of 45 to 55 mg/kg twice daily or 25 to 35 mg/kg three times daily with a meal. • Please refer to the Full Prescribing Information for specific dosing guidelines based on age and body weight. • Patients ≥ 13 years should refer to adult recommended dosing. |
Viracept Label |
| Fuzeon | enfuvirtide lyophilized powder 108 mg/vial | Fusion Inhibitors | Subcutaneous Injection | ≥ 11 kg | Recommended dosing is 2 mg per kg twice daily up to a maximum dose of 90 mg twice daily injected subcutaneously into the upper arm, anterior thigh or abdomen. Please see Full Prescribing Information for dosing recommendations based on body weight. | Fuzeon Label | |
| Selzentry* | maraviroc 25 mg, 75 mg, 150 mg, 300 mg | Entry Inhibitors - CCR5 co-receptor antagonist | Oral Tablet | ≥ 10 kg | ≥ 2 years | Dosing is based on body weight and concomitant medications administered twice daily with or without food and should not exceed the recommended adult dose. Please see the Full Prescribing Information for dosing details. |
Selzentry Label |
| Selzentry* | maraviroc 20 mg/mL | Entry Inhibitors - CCR5 co-receptor antagonist | Oral Solution | ≥ 10 kg | ≥ 2 years | Dosing is based on body weight and concomitant medications administered twice daily with or without food and should not exceed the recommended adult dose. Please see the Full Prescribing Information for dosing details. |
Selzentry Label |
| Isentress | raltegravir film-coated 400 mg | Integrase Inhibitors | Oral Tablet | ≥ 2 kg | If weighing at least 40 kg, and either treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily: • 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or • 400 mg film-coated tablet orally, twice daily or • 300 mg chewable tablets, twice daily If weighing at least 25 kg: One 400 mg film-coated tablet orally, twice daily. If unable to swallow a tablet, consider the chewable tablet. If at least 4 weeks of age and weighing at least 3 kg to less than 25 kg: Dosing based on body weight. For patients weighing between 11 and 20 kg, either the chewable tablet or the formulation for oral suspension can be used. For neonates (birth to 4 weeks [28 days] of age) weighing at least 2 kg: dosing based on body weight for oral suspension. Please see the Full Prescribing Information for details on dosing. |
Isentress Label | |
| Isentress HD | raltegravir HD film-coated 600 mg | Integrase Inhibitors | Oral Tablet | ≥ 40 kg | If weighing at least 40 kg, and either treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily: • 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or • 400 mg film-coated tablet orally, twice daily or • 300 mg chewable tablets, twice daily If weighing at least 25 kg: One 400 mg film-coated tablet orally, twice daily. If unable to swallow a tablet, consider the chewable tablet. If at least 4 weeks of age and weighing at least 3 kg to less than 25 kg: Dosing based on body weight. For patients weighing between 11 and 20 kg, either the chewable tablet or the formulation for oral suspension can be used. For neonates (birth to 4 weeks [28 days] of age) weighing at least 2 kg: dosing based on body weight for oral suspension. Please see the Full Prescribing Information for details on dosing. |
Isentress Label | |
| Isentress | raltegravir 25, 100 mg | Integrase Inhibitors | Oral Chewable Tablet | ≥ 2 kg | If weighing at least 40 kg, and either treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily: • 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or • 400 mg film-coated tablet orally, twice daily or • 300 mg chewable tablets, twice daily If weighing at least 25 kg: One 400 mg film-coated tablet orally, twice daily. If unable to swallow a tablet, consider the chewable tablet. If at least 4 weeks of age and weighing at least 3 kg to less than 25 kg: Dosing based on body weight. For patients weighing between 11 and 20 kg, either the chewable tablet or the formulation for oral suspension can be used. For neonates (birth to 4 weeks [28 days] of age) weighing at least 2 kg: dosing based on body weight for oral suspension. Please see the Full Prescribing Information for details on dosing. |
Isentress Label | |
| Isentress | raltegravir 100 mg/packet | Integrase Inhibitors | Oral Suspension | ≥ 2 kg | If weighing at least 40 kg, and either treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily: • 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or • 400 mg film-coated tablet orally, twice daily or • 300 mg chewable tablets, twice daily If weighing at least 25 kg: One 400 mg film-coated tablet orally, twice daily. If unable to swallow a tablet, consider the chewable tablet. If at least 4 weeks of age and weighing at least 3 kg to less than 25 kg: Dosing based on body weight. For patients weighing between 11 and 20 kg, either the chewable tablet or the formulation for oral suspension can be used. For neonates (birth to 4 weeks [28 days] of age) weighing at least 2 kg: dosing based on body weight for oral suspension. Please see the Full Prescribing Information for details on dosing. |
Isentress Label Information | |
| Tivicay* | dolutegravir 10 mg, 25mg, 50 mg | Integrase Inhibitors | Oral Tablet | ≥ 30 kg | Dosing based on body weight once to two times daily with or without food. Please see Full Prescribing Information for dosing details for treatment-naïve or treatment-experienced INSTI-naïve patients weighing at least 30kg. | Tivicay Label | |
| Tybost* | cobicistat 150 mg | CYP3A Inhibitor | Oral Tablet | ≥ 35 kg | 150 mg orally once daily with atazanavir 300 mg orally once daily given with food. TYBOST must be given in combination with atazanavir. Please see Full Prescribing Information for dosing details. | Tybost Label | |
| Tybost* | cobicistat 150 mg | CYP3A Inhibitor | Oral Tablet | ≥ 40 kg | 150 mg orally once daily and darunavir 800 mg orally once daily given with food. TYBOST must be given in combination with darunavir. Please see Full Prescribing Information for dosing details. | Tybost Label |